INSIGHTS ON DRUG DEVELOPMENT

• What Will It Take To Make MCED And MRD A Reality?

  Cancer mortality is declining, but the need for earlier action remains. Gain insight into how MCED and MRD are advancing cancer detection and surveillance, helping clinicians identify disease sooner.

• Sterilization Of APIs – The Alternative: Sterile Filtration Following Aseptic Processing

  When terminal sterilization isn't an option for heat- or radiation-sensitive APIs, sterile filtration with aseptic processing protects quality. Get the technical framework.

• Evaluating Clone Performance And Cell-Specific Productivity

  See how continuous process monitoring and automated at-line analytics support confident CHO clone ranking, consistent cultivation, and scale-up by connecting pH, viable cell density, and more.

• Overcoming Volume And Viscosity Barriers In Biologic Formulations

  Learn how advanced containment solutions support high-viscosity biologics, improve device compatibility, enhance injection performance, and address evolving drug delivery and patient care challenges.

• Patented Process For Olopatadine HCl API Intermediates

  7/15/2026

  See how this patented Wittig-based process for olopatadine HCl achieves Z/E isomer ratios up to 4:1, eliminating dangerous reagents like n-butyl lithium while cutting purification complexity.

• Unleash The Potential For Polyvinyl Alcohol In Spray Drying

  6/4/2025

  Discover how polyvinyl alcohol (PVA) addresses key formulation challenges in oral solid dosage forms to enhance solubility and stability across diverse APIs, which include emerging drug classes like PROTACs.

• Scientific Data Is Not AI‑Ready By Default

  6/26/2026

  Convert siloed laboratory data into trusted, AI-ready assets. Learn to enforce data integrity principles at the point of origin to streamline analytics and reduce GxP compliance risks.

• Accelerating Drug Development: Solid State Chemistry And Strategic Outsourcing

  5/6/2026

  Discover how phase‑appropriate solid‑state chemistry and strategic outsourcing reduce risk, speed development timelines, and enable confident solid‑form selection for complex small‑molecule programs.

• Best-In-Class Nanodevelopment Capabilities

  2/3/2025

  A highly specialized team excels in creating unique nanoparticles for both small and large molecule APIs. Leveraging cutting-edge technology, they produce nanoformed materials as small as 10 nanometers.